Alopecia areata - Alopeċja Areata
☆ Fir-riżultati ta' Stiftung Warentest tal-2022 mill-Ġermanja, is-sodisfazzjon tal-konsumatur b'ModelDerm kien biss ftit inqas milli b'konsultazzjonijiet bit-telemediċina mħallsa.
Alopeċja Areata (Alopecia areata) jidher fuq wara tal-qorriegħa. F'każijiet tipiċi, jidher f'daqqa b'wiċċ kompletament lixx u daqs ta '2-3 cm.
References
Alopecia areata hija kundizzjoni fejn is-sistema immuni tiegħek tattakka l-follikuli tax-xagħar tiegħek, li twassal għal telf temporanju tax-xagħar mingħajr ċikatriċi. Jista’ jidher bħala rqajja’ ta’ telf ta’ xagħar jew jaffettwa l-qorriegħa jew il-ġisem kollu tiegħek, b’impatt fuq madwar 2% tan-nies f’xi stadju ta’ ħajjithom. Il-ħati prinċipali jidher li huwa tqassim fil-protezzjoni naturali madwar il-follikuli tax-xagħar.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata hija kundizzjoni fejn is-sistema immuni tattakka l-follikuli tax-xagħar, u tikkawża telf ta 'xagħar fuq il-qorriegħa u partijiet oħra tax-xagħar tal-ġisem. Din taffettwa madwar 2% tan-nies madwar id-dinja. Filwaqt li jista 'jseħħ fi kwalunkwe età, huwa aktar komuni fit-tfal milli fl-adulti (1. 92% vs. 1. 47%) . In-nisa, speċjalment dawk 'il fuq minn 50, għandhom tendenza li jesperjenzawha aktar mill-irġiel. L-injezzjoni ta' kortikosterojdi direttament fiż-żoni affettwati wriet riżultati aħjar milli tapplikahom topikament.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Alopeċja areata hija maħsuba li hija marda awtoimmuni relatata mas-sistema immuni tal-follikuli tax-xagħar. Il-mekkaniżmu sottostanti jinvolvi nuqqas mill-ġisem li jagħraf iċ-ċelloli tiegħu stess, b'qerda sussegwenti medjata mill-immunità tal-follikulu tax-xagħar.
○ Trattament - Drogi OTC
Xi nies b'alopeċja areata ħafifa jirkupraw fi żmien sena mingħajr kura. Madankollu, ħafna nies jesperjenzaw rikorrenzi f'siti każwali fuq il-qorriegħa.
#Hydrocortisone cream
○ Trattament
L-injezzjonijiet ta 'sterojdi intralesjonali huma l-aktar trattament effettiv. L-immunoterapija tista 'tiġi ppruvata jekk jiġu affettwati żoni kbar tal-qorriegħa.
#Triamcinolone intralesional injection
#DPCP immunotherapy